Nephrology News
Novel Enteric Budesonide Reduces Proteinuria in IgAN
Overall, patients receiving TRF-budesonide saw a 24.4% reduction in their average urine protein creatinine ratio over 9 months.
By accepting you will be accessing a service provided by a third-party external to https://galencarepartners.com/